

7-5/2013/EU/WC-0143
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated:

To,

M/s Cipla Ltd.
Plot No. A-42 MIDC Patalganga Khalapur,
Raigad-410220, Maharashtra India

05 JUL 2022

SUB:- Written Confirmation of M/s Cipla Ltd. Plot No. A-42 MIDC Patalganga Khalapur , Raigad-410220, Maharashtra India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your online application no. WC/RE/2022/4219 submitted to CDSCO, West Zone and the recommendation received from DDC(I), West Zone office on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions: -

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.

5. The Written Confirmation will be withdrawn in the events of non-compliance of Standards.
6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
01	11	05 JUL 2022	08.09.2025

Yours faithfully,



(Dr. V. G. Somani)
Drugs Controller General (India)





Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site **M/s Cipla Ltd.**
Plot No. A-42 MIDC Patalganga Khalapur,
Raigad-410220, Maharashtra India

2. Manufacturer's licence number: (25)KD-620 & (28) KD-435

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

List of API(s):

As per Annexure 1

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (= GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

Date of Inspection of the plant: 06.05.2019 to 08.05.2019

The Written Confirmation remains valid until: 08.09.2025

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

Address of the issuing regulatory authority: Central Drugs Standard Control Organisation
FDA Bhawan, Kotla Road,
New Delhi- 110 002, India

Name and function of responsible person: Dr. V.G.Somani,
Drugs Controller General (India)

E-mail: dci@nic.in,
Telephone no.: +91-11-23236965
Fax no.: +91-11-23236973

Signature

05 JUL 2022

Stamp of the authority and date





Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s Cipla Ltd.
Plot No. A-42 MIDC Patalganga Khalapur,
Raigad-410220, Maharashtra India

List of APIs:

Sr. No.	Active substance (s)	Activity(ies)
1.	Artemether IHS/IP//Ph.Int	Manufacturing & Packing
2.	Artesunate IHS/IP//Ph.Int	Manufacturing & Packing
3.	Cetirizine Hydrochloride USP/BP/Ph. Eur./IP	Manufacturing & Packing
4.	Desloratidine IHS/BP/EP	Manufacturing & Packing
5.	Escitalopram oxalate IHS/IP/USP	Manufacturing & Packing
6.	Finasteride USP/BP/EP/IP	Manufacturing & Packing
7.	Levocetirizine Dihydrochloride IHS/IP	Manufacturing & Packing
8.	Lumefantrine IH/Ph.int	Manufacturing & Packing
9.	Praziquantel BP/IP/EP/USP	Manufacturing & Packing
10.	Venlafaxine HCl BP/IHS/EP	Manufacturing & Packing
11.	Citalopram Hydrobromide BP/Ph.Eur	Manufacturing & Packing

ITEM(S) Eleven (11) ONLY

The Written Confirmation remains valid until: 08.09.2025

Signature

Stamp of the authority and date



05 JUL 2022